Article

Non-Canonical Senescence Phenotype in Resistance to CDK4/6 Inhibitors in ER-Positive Breast Cancer

2025-11-10

Abstract excerpt

Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) have transformed the treatment landscape for estrogen receptor-positive (ER+) breast cancer, yet re-sistance remains a major clinical challenge. Although CDK4/6i induce G1 ar-rest and therapy-induced senescence (TIS), the exact nature of this senescent state and its contribution to resistance are not well understood. To explore this, we developed palbociclib- (2PR,...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3f4f0647-ff5b-5c0b-acbf-e733ea16220c
DOI: 10.20944/preprints202511.0669.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Non-Canonical Senescence Phenotype in Resistance to CDK4/6 Inhibitors in ER-Positive Breast CancerDOI 10.20944/preprints202511.0669.v1Read

Therapy-induced senescence in breast cancer: an overviewSemantic proximity Read

Pharmacological CDK4/6 inhibition unravels a p53-induced secretory phenotype in senescent cellsSemantic proximity Read

Harnessing the interaction between redox signaling and senescence to restrain tumor drug resistanceSemantic proximity Read

Pharmacological CDK4/6 inhibition reveals a p53‐dependent senescent state with restricted toxicitySemantic proximity Read

Senescent stromal cells promote cancer resistance through SIRT1 loss-potentiated overproduction of small extracellular vesiclesSemantic proximity Read

A senescence stress secretome is a hallmark of therapy-related myeloid neoplasm stromal tissue occurring soon after cytotoxic exposureSemantic proximity Read

CDK4/6 inhibition induces a senescence-associated secretory phenotype via delayed NF-κB activation.Semantic proximity Read

Stromal Senescence By Prolonged CDK4/6 Inhibition Potentiates Tumor GrowthSemantic proximity Read

Tumour-derived extracellular vesicles within the therapy-induced senescent secretome distinctly suppress breast cancer via DKK1-mediated inflammatory responseSemantic proximity Read

Targeting epiregulin in the treatment-damaged tumor microenvironment restrains therapeutic resistanceSemantic proximity Read

Pharmacological CDK4/6 inhibition promotes vulnerability to lysosomotropic agents in breast cancerSemantic proximity Read

GPNMB overexpression- a marker of resistance to CDK4/6 inhibitorsSemantic proximity Read